XML 64 R44.htm IDEA: XBRL DOCUMENT v3.6.0.2
Collaboration and Licensing Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Sep. 30, 2015
May 31, 2014
Oct. 31, 2012
Jun. 30, 2015
Jun. 30, 2016
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]          
Payment received on termination and return of rights $ 0        
AstraZeneca [Member]          
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]          
Upfront payment received     $ 75,000,000    
Amount of upfront payment for return of licenses       $ 15,000,000  
Amount of reimbursement paid for certain research and development expenses in consideration of acceleration of transfer of information and materials       10,000,000  
Recognized deferred revenue       $ 43,100,000  
Recognition of licensing and collaborative development revenue         $ 0
Sanofi [Member]          
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]          
Revenue recognized   $ 1,250,000